MODERN POSSIBILITIES OF APPLICATION OF PREPARATION NAVELBINE® IN THE TREATMENT OF METASTATIC BREAST CANCER
https://doi.org/10.17709/2409-2231-2016-3-2-10
Abstract
Drug therapy of disseminated forms of breast cancer involves the use of monoand polychemotherapy with the possible combination with target-therapy in various clinical situations. The article presents the choices of treatment approaches, demonstrated the efficacy and safety of chemotherapeutic regimens on the basis of vinorelbine
About the Author
L. V. Bolotina
Р. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Larisa V. Bolotina – MD., head of chemotherapeutical dept
For correspondence: P. Hertsen MORI – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation Address: 3, 2nd Botkinskiy proezd,
References
1. American Cancer Society. Global Cancer Facts & Figures. 3rd Edition. Atlanta: American Cancer Society; 2015: р. 41. Available at: http://oralcancerfoundation.org/facts/pdf/Us_Cancer_Facts.pdf (Accessed: 22.02.2016)
2. Ed by A.D. Kaprin, V. V. Starinskii, G. V. Petrova. Zlokachestvennye novoobrazovanija v Rossii v 2014 godu (zabolevaemost' i smertnost'). Moscow: P. Hertsen MORI, 2015. (Russian). Available at: http://www.oncology.ru/service/statistics/condition/2014.pdf (Accessed: 22.02.2016)
3. Cardoso F., Fallowfield L., Costa A., Castiglione M., Senkus E.; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22 Suppl 6: vi25–30. doi: 10.1093/annonc/mdr372.
4. Semiglazov V. F., Paltuev R. M., Semiglazov V. V., Dashyan G. A., Semiglazova T. Y., Krivorotko P. V., Nikolaev K. S. General St. Gallen 2015 guidelines for the treatment of early breast cancer (adapted by the experts of the Russian Society of Breast Oncologists). Women Reproductive System Tumors. 2015;11 (3):43– 60. (In Russ.) DOI: 10.17650/1994–4098–2015–11–3-43–60
5. Gligorov J., Doval D., Bines J., Alba E., Cortes P., Pierga J. Y., et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first line bevacizumab and docetaxel for patients with HER2 negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15 (12): 1351–1360. doi: 10.1016/S1470–2045(14)70444–9. Epub 2014 Sep 28.
6. Advanced Breast Cancer Third International Consensus Conference; 5–7 November 2015: Lisbon, Portugal.
7. Dear R., McGeechan K., Jenkins M., Barratt A., Tattersall M., Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2013 Dec 18; (12): CD008792. doi: 10.1002/14651858.CD008792.pub2
8. Geels P., Eisenhauer E., Bezjak A., Zee B., Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000; 18: 2395–2406.
9. Karamouzis M. V., Ioannidis G., Rigatos G. Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. Eur J Cancer Care (Engl). 2007 Sep; 16 (5): 433–438.
10. Park Y.H., Jung K.H., Im S. A., Sohn J.H., Ro J., Ahn J.H., et al. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSGBR07–02). Breast Cancer Res Treat. 2015; 152 (1): 77–85. doi: 10.1007/s10549–015–3450 z. Epub 2015 Jun 2.
11. Addeo R., Sgambato A., Cennamo G., Montella L., Faiola V., Abbruzzese A., et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 2010 Aug 1;10 (4):301–6. doi: 10.3816/CBC.2010.n.039.
12. Gnoni A., Silvestris N., Licchetta A., Santini D., Scartozzi M., Ria R., et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol. 2015; 95 (1): 46–61. doi: 10.1016/j.critrevonc.2015.01.008. Epub 2015 Jan 20.
13. Kerbel R. S., Kamen B. A. Anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4 (6): 423–436
14. Ghiringhelli F., Menard C., Puig P. E., Ladoire S., Roux S., Martin F., et al Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007; 56: 641–648.
15. Cazzaniga M. E., Torri V., Villa F., Giuntini N., Riva F., Zeppellini A., et al. Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: The phase I–II VICTOR 1 study. Int J Breast Cancer. 2014; 2014: 769–790. doi: 10.1155/2014/769790. Epub 2014 Jan 16.
16. O'Shaughnessy J., Miles D., Vukelja S., Moiseyenko V., Ayoub. JP., Cervantes G., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002; 20 (12): 2812–2823.
17. Nielsen D. L., Andersson M., Kamby C. HER2 overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer Treat Rev. 2009; 35 (2): 121–136.
18. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A. B., et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2 positive breast cancer: the HERNATA study. J Clin Oncol. 2011; 29 (3): 264–271. doi: 10.1200/JCO.2010.30.8213. Epub 2010 Dec 13
19. Bernardo G., Palumbo R., Bernardo A., Poggi G., Delmonte A., Teragni C., et al. Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast … presented at the 31st ESMO Congress, Istanbul, Turkey, 29 September–3 October 2006.
20. Bartsch R., Wenzel C., Altorjai G., Pluschnig U., Bachleitner-Hoffmann T., Locker G.J., et al. Results from an observational trial with oralvinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Research and Treat. 2007; 102 (3): 375–381.
21. Heinemann V., Di Gioia D., Vehling-Kaiser U., Harich H.D., Heinrich B., Welt A., et al. A prospective multicenter phase II study of oral and i. v. vinorelbine plus trastuzumab as first-line therapy in HER2 overexpressing metastatic breast cancer. Ann Oncol. 2011; 22 (3): 603–608. doi: 10.1093/annonc/mdq409. Epub 2010 Aug 19.
22. Illarramendi J.J., Blancas I., Bueso P., Carabantes F., Polo Marques E., Ciruelos Gil E., et al. Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first-or second-line treatment. J Clin Oncol. 2010; 28.
Review
For citations:
Bolotina L.V. MODERN POSSIBILITIES OF APPLICATION OF PREPARATION NAVELBINE® IN THE TREATMENT OF METASTATIC BREAST CANCER. Research and Practical Medicine Journal. 2016;3(2):71-77. (In Russ.) https://doi.org/10.17709/2409-2231-2016-3-2-10
Views:
1493
Email this article 